Meprobamate is a white powder with a characteristic odor and a bitter taste. It is slightly soluble in water, freely soluble in acetone and alcohol, and sparingly soluble in ether.
Meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic.
The effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.
Media Articles Related to Meprobamate
Post-transplant anxiety linked to complex instructions, caregiver empathy
Source: Anxiety / Stress News From Medical News Today [2016.08.19]
Some anxiety is perfectly normal for kidney transplant patients, but new research suggests that medical staff can help patients feel more at ease when they leave the hospital and that could...
Watching cartoons could help children overcome anxiety of dental treatment
Source: Anxiety / Stress News From Medical News Today [2016.08.08]
Watching cartoons through video glasses during dental treatment could help lessen children's anxiety and distress as well as reducing disruptive behaviour, according to a randomized controlled...
When drug treatment of social anxiety is not sufficient: The role of psychotherapy
Source: Anxiety / Stress News From Medical News Today [2016.07.27]
A randomized controlled study has evaluated the role of psychotherapy in patients whose social anxiety did not respond to drug treatment.
Palliative care-led meetings do not reduce anxiety, depression of families of patients with chronic critical illness
Source: Anxiety / Stress News From Medical News Today [2016.07.06]
Among families of patients with chronic critical illness, the use of palliative care-led informational and emotional support meetings compared with usual care did not reduce anxiety or depression...
Low attention control in early adolescence is a genetic risk factor for anxiety disorders
Source: Anxiety / Stress News From Medical News Today [2016.06.22]
University of Texas at Arlington researchers have found that low attention control in early adolescence is related to a genetic risk factor for four different anxiety disorders.
Published Studies Related to Meprobamate
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. [2003.06]
Implementation of regulations to control the prescribing of benzodiazepines in New York State in 1989 resulted in a 55% decrease in benzodiazepine prescribing, with a concomitant increase in the rates of prescribing older sedative-hypnotic compounds such as butabarbital (30% increase) and meprobamate (125% increase).
Reports of Suspected Meprobamate Side Effects
Toxicity TO Various Agents (28),
Respiratory Arrest (15),
Cardiac Arrest (15),
Accidental Death (14),
Drug Abuse (11),
Completed Suicide (11),
Multiple Drug Overdose Accidental (5),
Pulmonary Congestion (5),
Pulmonary Oedema (4), more >>
Page last updated: 2016-08-19